Feb. 22, 2018 Merck bags oncolytics player Viralytics

Column:Industry Trends Time:2018-03-16
On Feb. 22, 2018, Merck and Viralytics announced acquisition agreement and the proposed acquisition values the total issued shares in Viralytics at approximately AUD 502 million (USD 394 million).

        On Feb. 22, 2018, Merck and Viralytics announced acquisition agreement and the proposed acquisition values the total issued shares in Viralytics at approximately AUD 502 million (USD 394 million).

1.jpg

        On completion of the transaction, Viralytics will become a wholly-owned subsidiary of Merck, and Merck will gain full rights to CAVATAK® (CVA21), Viralytics’s investigational oncolytic immunotherapy. CAVATAK is based on Viralytics’s proprietary formulation of an oncolytic virus (Coxsackievirus Type A21) that has been shown to preferentially infect and kill cancer cells.

CAVATAK is currently being evaluated in multiple Phase 1 and Phase 2 clinical trials, both as an intratumoral and intravenous agent, including in combination with Merck’s KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy. Under an agreement between Viralytics and a subsidiary of Merck, announced in November 2015, a study is investigating the use of the CAVATAK and KEYTRUDA combination in melanoma, prostate, lung and bladder cancers.

On completion of the transaction, Viralytics will become a wholly-owned subsidiary of Merck, and Merck will gain full rights to CAVATAK® (CVA21), Viralytics’s investigational oncolytic immunotherapy.

2.jpg

“Viralytics’s approach of engaging the innate immune system to target and kill cancer cells complements our immuno-oncology strategy, which is focused on the rapid advancement of innovative monotherapy approaches and synergistic combinations to help the broadest range of cancer patients,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “We are eager to further build on Viralytics’s science as we continue our efforts to harness the immune system to improve long-term disease control and survival outcomes for people with cancer.”

      “This proposed acquisition culminates years of dedicated work by the Viralytics team and represents an opportunity for significant value creation for our shareholders. Viralytics is proud to have progressed its lead investigational candidate CAVATAK to Phase 1 and Phase 2 clinical trials and, we believe that Merck, the leader in immuno-oncology, is best suited to advance CAVATAK for the benefit of patients globally, and to realize its potential,” said Dr. Malcolm McColl, managing director and chief executive officer, Viralytics.

      Hope this acquisition will bring innovative cancer immunotherapy to cancer patients.

Reference 

1.http://med.sina.com/article_detail_100_2_41521.html

2.https://endpts.com/merck-executes-an-ma-deal-for-its-pd-1-cancer-franchise-buying-an-oncolytics-biotech-for-394m/